Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment

Yazar
Kao, Jia-Horng
Fehmi, Tabak
Buti, Maria
Izumi, Namiki
Lim, Young-Suk
Janssen, Harry
Streinu-Cercel, Adrian
Ma, Xiaoli
Nurmukhametova, Elena
Jablkowski, Maciej
Suri, Vithika
Flaherty, John F.
Lau, Audrey
Gaggar, Anuj
Mo, Shuyuan
Chaudhuri, Abhijit
Fung, Scott
Chuang, Wan-Long
Gane, Edward
Üst veri
Tüm öğe kaydını göster
Bağlantı
http://hdl.handle.net/20.500.12627/27896
https://doi.org/10.1016/s0618-8278(19)30903-x
Koleksiyonlar